Delta-Fly Pharma, Inc. announced that the following is the current status of the interim analysis of a Phase III study of DFP-10917 monotherapy in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US. As there are a long-term surviving patients in the 150 patients enrolled in this study, the company intend to continue to follow up these patients without any data cut-off for the time being to determine the final overall survival (OS) results of the study. The company ask for understanding that under a randomized and controlled study, the company is unable to identify at this stage whether these surviving patients are in the DFP-10917 group or the control group (NCT03926624).

The company look forward to showing the results when the data is ready to disclose.